Volume 17, Number 6—June 2011
Research
Use of Antiviral Drugs to Reduce Household Transmission of Pandemic (H1N1) 2009, United Kingdom1
Table 4
Univariate and multivariate analysis of pandemic (H1N1) 2009 virus infection SAR for virologically confirmed cases of pandemic (H1N1) 2009 virus infection, by gender, age group, and prophylaxis, United Kingdom, 2009*
Variable |
No. contacts† |
No. secondary
case-patients |
Univariate analysis |
Multivariate analysis |
|||
SAR, % (95% CI) |
p value‡ |
OR (95% CI) |
p value |
||||
Sex, n = 745 | |||||||
M | 364 | 37 | 10.2 (7.5–13.7) | 1.0, baseline | |||
F |
381 |
25 |
6.6 (4.0–10.7) |
0.08 |
1.0 (0.5–2.0) |
0.96 |
|
Age, y | |||||||
<16 | 212 | 40 | 18.9 (14.2–24.7) | 18.2 (3.9–85.5) | |||
16–49 | 378 | 20 | 5.3 (3.1–9.0) | 3.5 (0.7–16.2) | |||
>50 |
171 |
2 |
1.2 (0.3–4.7) |
<0.001 |
1.0, baseline |
<0.001 |
|
Prophylaxis, n = 587 | |||||||
No | 143 | 45 | 31.5 (24.4–39.5) | 1.0, baseline | |||
Yes |
444 |
8 |
1.8 (0.8–3.9) |
<0.001 |
0.05 (0.02–0.09) |
<0.001 |
|
Primary case-patient treatment | |||||||
>48 h | 453 | 48 | 10.6 (8.1–13.8) | 1.0, baseline | |||
<48 h |
308 |
14 |
4.5 (2.5–8.1) |
0.003 |
0.30 (0.13–0.68) |
0.004 |
|
Total | 761 | 62 | 8.1 (6.4–10.3) |
*n = 761 except as indicated. Hosmer-Lemeshow goodness-of-fit test for multivariate model, p = 0.751. SAR, secondary attack rate; CI, confidence interval; OR, odds ratio.
†Excludes co-primary cases.
‡Indicates overall p value for differences by group.
1Elements of this work were presented at the Health Protection Agency Annual Conference in 2009. An abstract was presented at the International Conference on Emerging Infectious Diseases, Atlanta, Georgia, USA, 2010.